ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

J&J, Achillion Join For Hepatitis Drugs

by Michael McCoy
May 25, 2015 | APPEARED IN VOLUME 93, ISSUE 21

Johnson & Johnson’s Janssen Pharmaceuticals unit has agreed to license hepatitis C drug assets from Achillion Pharmaceuticals, a developer of small-molecule drugs for infectious diseases. Janssen will invest $225 million in Achillion stock plus up to $1.1 billion in potential development, regulatory, and sales milestone payments. Achillion’s lead compound, ACH-3102, is a second-generation NS5A inhibitor now in Phase II clinical trials. J&J already markets the older treatment Olysio, but the firm isn’t a player in the newer all-oral market.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment